Osteoarthritis / joint degeneration
Cartilage loss plus low-grade joint inflammation.
Decision support, not prescription. You decide.
Candidate agents
6 agents · tap to expand▶BPC-157LeadEmergingSynthetic gastric pentadecapeptide used off-label as an intra-articular or peri-articular injection for knee OA pain and soft-tissue repair; treat as experimental, since human OA data amount to a single small uncontrolled retrospective series.expand
Synthetic gastric pentadecapeptide used off-label as an intra-articular or peri-articular injection for knee OA pain and soft-tissue repair; treat as experimental, since human OA data amount to a single small uncontrolled retrospective series.
▸Full clinical story
Preclinically it drives angiogenesis, collagen and fibroblast activity, and tendon/ligament/cartilage healing while dampening inflammatory cytokines and nitric-oxide signaling, which maps onto the repair-plus-anti-inflammation lever in OA. No OA-specific chondrogenic mechanism has been demonstrated in humans.
Anecdotal: the only human OA data is uncontrolled. The best human evidence is a retrospective chart review of 17 knee-pain patients (16 surveyed) in which ~87% reported relief after intra-articular BPC-157 with or without thymosin beta-4, but there were no controls, no imaging, and mixed diagnoses. A 2025 systematic review found 35 of 36 included studies were preclinical (1 clinical) with no clinical safety data. Any therapeutic signal rests on mechanism plus one uncontrolled report, so this is graded anecdotal rather than emerging.
Anecdotal community signal only: BPC-157 is widely used in peptide/biohacker and grey-market sports-medicine circles, injected subcutaneously near the joint or intra-articularly, frequently stacked with TB-500/thymosin beta-4. Users report less pain and faster return to activity, but this is uncontrolled self-report, not evidence.
Context, not a protocol: commonly cited regimens are ~250-500 mcg intra-articular or peri-articular, or ~200-500 mcg/day subcutaneously in 2-6 week cycles. No validated OA dosing exists.
Unapproved and WADA-banned (relevant for tested athletes); grey-market compounding carries contamination and sterility risk that is especially serious for intra-articular injection (septic arthritis). No long-term human safety or drug-interaction data.
Biologically plausible and popular, but for OA it rests on a single small uncontrolled series. Reasonable to discuss as experimental, not to present as proven; controlled trials are the missing piece.
▶AICARPreclinicalAMPK-activating AMP analog used as a mechanistic tool to demonstrate chondroprotection in OA; in-vitro/ex-vivo only, not a clinical joint therapy.expand
AMPK-activating AMP analog used as a mechanistic tool to demonstrate chondroprotection in OA; in-vitro/ex-vivo only, not a clinical joint therapy.
▸Full clinical story
AICAR activates AMPK, which restrains the ER-stress mediator CHOP; in chondrocytes this blunts IL-1beta- and biomechanical-injury-induced nitric oxide, MMP-3 and apoptosis, linking metabolic AMPK tone to reduced cartilage catabolism.
Preclinical. A single mechanistic study in human OA cartilage, bovine chondrocytes and autopsy chondrocytes showed AICAR limited injury-induced CHOP and catabolic responses, with the authors framing it as rationale for AMPK activators already in the clinic (salicylates, methotrexate). There are no AICAR OA trials. Grade preclinical is confirmed.
Anecdotal community signal: AICAR is known in the endurance/exercise-mimetic doping world, not for OA; there is no meaningful joint-focused community use, and it is WADA-banned.
No OA dosing exists; not applicable, as systemic AICAR is impractical, expensive, and unproven.
WADA-prohibited; systemic AMPK activation with unknown human safety. The real translational bet is on oral AMPK activators such as metformin, not AICAR itself.
Valuable as proof-of-mechanism that AMPK activation is chondroprotective, but AICAR itself is a lab tool; the clinically relevant readout is whether AMPK activators like metformin help patients.
▶MOTS-cPreclinicalMitochondria-derived peptide studied as a chondroprotective agent in OA; strictly preclinical with no human OA data.expand
Mitochondria-derived peptide studied as a chondroprotective agent in OA; strictly preclinical with no human OA data.
▸Full clinical story
In OA models MOTS-c improves chondrocyte mitochondrial function and activates Nrf2, suppressing the TXNIP/NLRP3 inflammasome and pyroptosis while cutting matrix-degrading MMPs and preserving extracellular matrix, directly targeting the mitochondrial-dysfunction-plus-low-grade-inflammation axis of cartilage loss.
Preclinical only. A 2025 study in a mouse OA model and LPS-stimulated chondrocytes showed reduced cartilage degeneration via the Nrf2/TXNIP/NLRP3 pathway. There are no human studies. Grade preclinical is confirmed.
Anecdotal community signal: MOTS-c is used in longevity and metabolic biohacking circles (subcutaneous, for metabolic/exercise goals), but essentially no OA-specific community use is reported. It is not established for joints.
No OA dosing exists. Metabolic/longevity users cite ~5-10 mg subcutaneously 2-3x/week in cycles, which is context only and unvalidated for joints.
No human OA safety data; unapproved research peptide. Theoretical concerns around chronic Nrf2 pathway modulation and unknown interactions with metabolic drugs.
Mechanistically attractive for the mitochondrial/inflammasome side of OA, but it is a single-species preclinical story: a research lead, not a clinical option.
▶MetforminEmergingOral AMPK activator and the most clinically advanced repurposing candidate for knee OA, particularly in overweight/obese patients, now backed by a positive but modest randomized trial.expand
Oral AMPK activator and the most clinically advanced repurposing candidate for knee OA, particularly in overweight/obese patients, now backed by a positive but modest randomized trial.
▸Full clinical story
Metformin activates AMPK (the same pathway AICAR probes), with anti-inflammatory, senescence-limiting and putative cartilage-protective effects; the metabolic OA phenotype (obesity plus low-grade inflammation) is where this rationale is strongest.
Emerging, now with human RCT support. A 2025 JAMA double-blind RCT (n=107, overweight/obese knee OA) found metformin 2000 mg/day reduced VAS knee pain versus placebo (between-group difference -11.4 mm; effect size 0.43; P=.01), though the effect fell below the 15 mm minimal clinically important difference and the trial was modest, with authors calling for confirmation. An Osteoarthritis Initiative cohort linked metformin use to slower medial cartilage volume loss, while an earlier primary-care cohort of type 2 diabetics found no effect on OA incidence (adjusted HR 1.02). Net: a promising symptom signal that is not yet definitive or guideline-endorsed, so emerging is the honest grade.
Anecdotal community signal: metformin is already prescribed on-label for diabetes and metabolic health and is heavily discussed in longevity circles; some clinicians trial it off-label for metabolic-phenotype OA, but this runs ahead of formal guidelines.
Trial context: 2000 mg/day was used in the JAMA RCT; standard diabetes titration is 500 mg up to ~2000 mg/day to limit GI effects. This is context, not an OA protocol.
GI intolerance (diarrhea, abdominal discomfort) is common; chronic use can deplete vitamin B12; use caution or avoid in significant renal impairment and hold around iodinated contrast. Benefit was shown mainly in the overweight/obese phenotype and may not generalize to lean OA.
The strongest repurposing story in this set: one positive modest RCT plus supportive cohort data in overweight/obese knee OA. Reasonable to consider off-label in that phenotype while awaiting a larger confirmatory trial.
- Metformin for Knee Osteoarthritis in Patients With Overweight or Obesity: A Randomized Clinical Trial. ↗
- Association between metformin use and disease progression in obese people with knee osteoarthritis: data from the Osteoarthritis Initiative-a prospective cohort study. ↗
- Does metformin protect against osteoarthritis? An electronic health record cohort study. ↗
▶alpha-MSHPreclinicalPOMC-derived melanocortin peptide explored as an anti-inflammatory/chondroprotective agent in OA; evidence is preclinical (in-vitro human chondrocytes, with only indirect animal support).expand
POMC-derived melanocortin peptide explored as an anti-inflammatory/chondroprotective agent in OA; evidence is preclinical (in-vitro human chondrocytes, with only indirect animal support).
▸Full clinical story
Human OA chondrocytes express melanocortin receptors; alpha-MSH down-modulates TNF-alpha/IL-1beta-driven MMP-3 and iNOS gene expression and raises TIMP-3, biasing the joint toward matrix preservation over catabolism.
Preclinical (in vitro). One study on cytokine-stimulated human OA chondrocytes showed the anti-catabolic pattern above, but with notable discrepancies between gene expression and secreted protein (for example, no drop in nitric oxide or IL-6/IL-8 release), leaving the true effect size uncertain. A review situates melanocortins among candidate neuroendocrine OA targets and notes anti-inflammatory actions of alpha-MSH in animal arthritis/OA models, but there is no dedicated intra-articular animal efficacy work and no human trials. Grade preclinical is confirmed.
Anecdotal community signal: alpha-MSH analogs (melanotan) are used recreationally for tanning and libido, not joints; there is essentially no OA-specific off-label use. The tanning peptides should not be conflated with a joint therapy.
No OA dosing exists; not applicable.
Melanocortin agonists carry pigmentation, blood-pressure/cardiovascular, and priapism concerns, and unregulated melanotan products are frequently impure. None of this has been evaluated for intra-articular or OA use.
An interesting anti-inflammatory mechanism in a dish with only indirect animal support and nothing more; far from a clinical OA agent.
Not recommended for this condition
Shown to close the loop — the evidence points the wrong way here.
▶Thymosin Beta-4EmergingIn OA, thymosin beta-4 reads as a severity biomarker and possible driver of cartilage degradation, not a validated repair therapy, so the honest framing is biomarker/caution.expand
In OA, thymosin beta-4 reads as a severity biomarker and possible driver of cartilage degradation, not a validated repair therapy, so the honest framing is biomarker/caution.
▸Full clinical story
Serum and synovial-fluid thymosin beta-4 rise with radiographic severity, and mechanistically its TMSB4 pseudogene lncRNA (lncRNA-MSR) is induced by mechanical stress and acts as a competing endogenous RNA sponging miR-152 to upregulate TMSB4, promoting matrix and cartilage degradation. It tracks and may propagate joint damage.
Emerging as a biomarker. A case-control study (216 knee OA vs 152 controls) showed serum and synovial-fluid thymosin beta-4 correlate with Kellgren-Lawrence grade, and a mechanistic study in patient cartilage and chondrocytes showed the lncRNA-MSR/TMSB4 axis drives degradation. These are biomarker and mechanism data, not therapeutic trials, so the direction is biomarker rather than therapeutic.
Anecdotal community signal: TB-500 (a thymosin beta-4 fragment) is heavily used in the peptide/sports-injury community, injected subcutaneously or near joints for healing and often stacked with BPC-157, with users reporting recovery benefits. This is unproven for OA and sits in tension with biomarker data showing higher thymosin beta-4 marks worse disease.
Community TB-500 dosing (context only): roughly 2-2.5 mg subcutaneously 1-2x/week loading then weekly maintenance. There is no OA-validated dosing, and the biomarker data give a reason for caution.
The severity-biomarker and degradation-driver signals argue against assuming thymosin beta-4/TB-500 is chondroprotective. Products are grey-market, WADA-banned, and raise theoretical concerns about promoting matrix turnover and angiogenesis; the community healing narrative should not be presented as OA evidence.
In OA, thymosin beta-4 is best understood as a marker of, and possible contributor to, cartilage degradation: useful as a severity signal, while the popular TB-500 repair use is unproven and mechanistically counterintuitive for the joint.
Matching protocol templates
Browse all →Endurance performance, fat oxidation, VO2 max
Fat loss, cellular energy enhancement, metabolic reset
Body recomposition, injury recovery, fat trimming
The platform surfaces evidence, community signal and peer outcomes with enforced cautions. It never decides treatment — the licensed clinician orders labs, writes notes, and prescribes.